| Literature DB >> 30055570 |
Xiaojia Xu1, Yulian Li2, Yaping Liang1, Mingjuan Yin1, Zuwei Yu2, Yan Zhang1, Lingfeng Huang1, Jindong Ni3.
Abstract
BACKGROUND: While vaccination remains the most effective method to control hepatitis B virus (HBV) infection, 5-10% of recipients exhibit non-responsiveness to the HB vaccine. Immunological analysis of strong, weak or absent protective antibody responses to the HB vaccine should provide insights into the mechanisms that contribute to non-responsiveness.Entities:
Keywords: Follicular helper T cells; Hepatitis B vaccine; MiR-17–92
Mesh:
Substances:
Year: 2018 PMID: 30055570 PMCID: PMC6064088 DOI: 10.1186/s12865-018-0263-y
Source DB: PubMed Journal: BMC Immunol ISSN: 1471-2172 Impact factor: 3.615
Fig. 1Gating strategy for the analysis of cTfh cells and plasma cells. a Representative flow cytometry plots from PBMC showing the gating scheme for isolating T cell. b Representative flow cytometry plots from PBMC showing the gating scheme for isolating B cell
The result of one way repeated measures analysis
| Day 0 | Day 7 | Day 14 |
|
| |
|---|---|---|---|---|---|
| HBsAb titers (IU/ml) | 57.87 ± 37.93 | 249.16 ± 125.95 | 667.39 ± 312.78 | 48.60 | < 0.001 |
| The percentage of PD-1+ICOS+ cTfh cells | 6.17 ± 1.17 | 7.68 ± 1.62 | 7.46 ± 2.20 | 5.62 | 0.014 |
| The percentage of Plasma cells | 20.82 ± 5.03 | 22.31 ± 6.07 | 21.66 ± 6.04 | 2.54 | 0.114 |
| The expression of miR-92a-1 | 18.63 ± 0.91 | 18.35 ± 0.96 | 19.55 ± 0.76 | 3.36 | 0.076 |
| The expression of miR-20a | 12.32 ± 0.90 | 12.01 ± 1.02 | 13.11 ± 0.68 | 3.42 | 0.067 |
| The expression of miR-19a | 13.19 ± 1.83 | 11.11 ± 1.05 | 12.50 ± 0.75 | 3.94 | 0.048 |
| The expression of miR-19b-1 | 19.18 ± 1.25 | 18.52 ± 1.06 | 19.91 ± 0.92 | 3.37 | 0.069 |
| The expression of miR-18a | 17.84 ± 0.63 | 17.86 ± 0.96 | 19.38 ± 0.93 | 10.37 | 0.002 |
| The expression of miR-17 | 10.55 ± 0.70 | 10.37 ± 0.72 | 11.44 ± 0.77 | 5.25 | 0.023 |
F: The statistics of one way repeated measures analysis
Fig. 2Dynamic changes of HBsAb titers, PD-1+ICOS+ cTfh cells, plasma cells and miR-17~ 92 after HBV vaccination. a The level of HBsAb titers in different points (day 0, 7, 14). b The percentage of PD-1+ICOS+ cTfh cells. c The percentage of plasma cells. d The level of miR-92a-1 in CD4+ T cells. e The level of miR-20a in CD4+ T cells. f The level of miR-19a in CD4+ T cells. g The level of miR-19b-1 in CD4+ T cells. h The level of miR-18 in CD4+ T cells. i The level of miR-17 in CD4+ T cells.*, P < 0.05; **, P < 0.01; ***, P < 0.001; n.s., no significant differences
Fig. 3The correlation between PD-1+ICOS+ cTfh cells and miRNA in CD4+ T cells. a The correlation of PD-1+ICOS+ cTfh cells with the level of miR-17 was analyzed. b The correlation of PD-1+ICOS+ cTfh cells with the level of miR-18a was analyzed
miR-17~ 92 correlated with the percentage of PD-1+ICOS+ cTfh cells
|
|
| |
|---|---|---|
| PD-1+ICOS+ cTfh cells and miR-92a-1 | 0.228 | 0.254 |
| PD-1+ICOS+ cTfh cells and miR-20a | 0.197 | 0.306 |
| PD-1+ICOS+ cTfh cells and miR-19a | −0.022 | 0.910 |
| PD-1+ICOS+ cTfh cells and miR-19b-1 | 0.160 | 0.408 |
| PD-1+ICOS+ cTfh cells and miR-18a | 0.452 | 0.014 |
| PD-1+ICOS+ cTfh cells and miR-17 | 0.372 | 0.047 |
Fig. 4The correlation between the HBsAb titers and PD-1+ICOS+ cTfh cells, miR17~ 92 in CD4+ T cells. a The correlation of HBsAb titers with PD-1+ICOS+ cTfh cells was analyzed. b The correlation of HBsAb titers with miR-92a-1was analyzed. c The correlation of HBsAb titers with miR-20a was analyzed. d The correlation of HBsAb titers with miR-19b-1 was analyzed. e The correlation of HBsAb titers with miR-18a was analyzed. f The correlation of HBsAb titers with miR-17 was analyzed
HBsAb titers correlated with cTfh cells and miR-17~ 92
|
|
| |
|---|---|---|
| HBsAbtiters and PD-1+ICOS+cTfh cells | 0.372 | 0.033 |
| HBsAb titers and miR-92a-1 | 0.464 | 0.013 |
| HBsAb titers and miR-20a | 0.502 | 0.004 |
| HBsAb titers and miR-19a | 0.156 | 0.401 |
| HBsAb titers and miR-19b-1 | 0.558 | 0.001 |
| HBsAb titers and miR-18a | 0.545 | 0.002 |
| HBsAb titers and miR-17 | 0.492 | 0.006 |
Demographic characteristics of study cohort
|
| 12 |
|---|---|
| Gender (M/F) | 6/6 |
| Age (years) | 28.83 ± 3.95 |
| BMI | 21.81 ± 3.54 |
Primers
| Gene | Primer sequence (5′ - 3′) |
|---|---|
| U6 RT | AACGCTTCACGAATTTGCGT |
| U6 Forward | CTCGCTTCGGCAGCACA |
| U6 Reverse | AACGCTTCACGAATTTGCGT |
| miR-17-5p RT | CCTGTTGTCTCCAGCCACAAAAGAGCACAATATT |
| miR-17-5p Forward | GCGGCCAAAGTGCTTACAGTG |
| miR-17-5p Reverse | CAGCCACAAAAGAGCACAAT |
| miR-18a-5p RT | CCTGTTGTCTCCAGCCACAAAAGAGCACAATATT |
| miR-18a-5p Forward | CGGGCTAAGGTGCATCTAGTG |
| miR-18a-5p Reverse | CAGCCACAAAAAGAGCACAAT |
| miR-19a-3p RT | CCTGTTGTCTCCAGCCACAAAAGAGCACAATATTT |
| miR-19a-3p Forward | CGCCGAGTTTTGCATAGTTG |
| miR-19a-3p Reverse | CAGCCACAAAAGAGCACAAT |
| miR-19b-1-5p RT | CCTGTTGTCTCCAGCCACAAAAGAGCACAATATTTC |
| miR-19b-1-5p Forward | GCGGCAGTTTTGCAGGTTTGC |
| miR-19b-1-5p Reverse | CAGCCACAAAAGAGCACAAT |
| miR-20a-5p RT | CCTGTTGTCTCCAGCCACAAAAGAGCACAATATTTCA |
| miR-20a-5p Forward | CGGGCTAAAGTGCTTATAGTG |
| miR-20a-5p Reverse | CAGCCACAAAAGAGCACAAT |
| miR-92a-1-5p RT | CCTGTTGTCTCCAGCCACAAAAGAGCACAATATTTCAG |
| miR-92a-1-5p Forward | CGCCGAGGTTGGGATCGGTTG |
| miR-92a-1-5p Reverse | CAGCCACAAAAGAGCACAAT |